![]() “The study clearly proves that baricitinib can decrease the amount of insulin required by patients with early type one diabetes and decrease the variability of blood sugars,” Messer added. “There are similarities between this drug and teplizumab (TZIELD), which is already on the market for a similar indication.” “The class of JAK inhibitors, in general, shows promise for the preservation of beta cell function (the cells in the pancreas that produce insulin) in patients with type one diabetes,” she told Medical News Today. Caroline Messer, an endocrinologist at Northwell Lenox Hill Hospital in New York who also was not involved in the research, agreed. Patients treated with this agent should continue to monitor their blood glucose as indicated and as required based on their treatment regime.”ĭr. “The study showed decreased needs for insulin but not resolution or ‘cure’ of diabetes. In this study, we saw decreased dosages, but patients had to continue using insulin nevertheless,” Sifonte told Medical News Today. “It remains to be seen whether treating patients earlier in their process may lead to delaying the need for insulin. “I would like to see further studies showing similar or better efficacy.” Eliud Sifonte, an endocrinologist at NYU Langone Medical Associates - West Palm Beach in Florida who was not involved in the research. “These are exciting findings since the only medication approved by the FDA to delay the onset of clinical type 1 diabetes is an infusion,” said Dr. The researchers noted that there was too much irreversible damage by the time of diagnosis to allow for the complete cessation of insulin therapy in participants. The remainder did but with lower levels, the researchers said.īaricitinib is not a cure for type 1 diabetes Three participants did not need insulin therapy by the end of the trial. There was a decreased need for insulin therapy.The percentage of time the glucose level stayed in the target range with higher.The variability in glucose level was lower.The researchers reported that insulin production continued when the participants remained on the medication.Īdditional findings for those taking baricitinib included: Vincent’s Institute and an author of the study, in a press release.ĭuring the study, children and young adults who received a diagnosis of type 1 diagnosis within the previous 100 days received either baricitinib or a placebo for 48 weeks. We showed that baricitinib is safe and effective at slowing the progression of type 1 diabetes in people who have been recently diagnosed,” said Tom Kay, PhD, a professor at St. We wanted to see whether we could protect the further destruction of these cells by the immune system. “When type 1 diabetes is first diagnosed there is a substantial number of insulin-producing cells still present. ![]() In the new clinical trial, researchers said that baricitinib can effectively preserve the body’s insulin production and suppress the progression of type 1 diabetes when treatment begins within 100 days of diagnosis. ![]() Details from the research on potential type 1 diabetes drug ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |